ZymoGenetics News

It's earnings season -- and here's a preview of the top storylines I'll be following on the blog.

Henry Paulson testifying Tuesday before the Senate Banking Committee. COMMENT By Robert D. Novak Thursday, July 17, 2008; Page A21 As financial storm signals appeared the past 18 months, some Bush officials ...

During yesterday's ZymoGenetics conference call to announce the company's $100 million financing deal , executives repeatedly referred to "transactions" or "business development objectives" in the works that ...

ZymoGenetics said this morning that it had reached a deal that will give it access to $100 million over the next 18 months.

ZymoGenetics, Inc. , today announced that it has received a $100 million funding commitment from Deerfield Management, a leading healthcare investment organization and a significant ZymoGenetics' shareholder.

Fourth in a five-day series. I asked seven of the top biotech leaders in the city to name the three colleagues who they thought were the most influential players in the industry here.

I reporter Joe Tartakoff continues his series on the most influential in Seattle biotech, highlighting ZymoGenetics CEO Bruce Carter, with one nominee calling him "the dean of all the corporate executives in ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting - SEATTLE-- --ZymoGenetics, Inc.

As I've mentioned before on the blog, it can be difficult to gauge trends in the biotech job market here because while mass lay offs are usually announced , mass hirings usually are not.

Merck Serono and development partner ZymoGenetics have initiated a Phase II/III trial of atacicept in patients with systemic lupus erythematosus to evaluate the efficacy and safety of the drug for the treatment ...

ZymoGenetics, Inc. announced today that Heather L. Franklin has been named Senior Vice President, Business Development and will serve as a member of - 06/05/2008 - 04:30 PM FOSTER CITY, Calif.-- --Synactive, ...

In December 2006, Seattle Genetics reported preliminary data from a phase one study of the company's SGN-40 treatment in patients with non-Hodgkin lymphoma.

Susan W. Specht, MBA, 206-442-6592 Director, Corporate Communications or Michael Fitzpatrick, 206-442-6702 Associate Director, Corporate Communications ZymoGenetics, Inc.

Kevin DeGeeter, an analyst at Oppenheimer & Co., put out a report today saying that Recothrom, ZymoGenetics' treatment to stop bleeding during surgery, had $92,589 in April sales, substantially below his ...

Main Category: Blood / Hematology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 29 May 2008 - 15:00 PDT ZymoGenetics, Inc.

Tuesday's stocks in the news The Blackstone Group and Apollo are reported to be discussing a possible deal to buy Chemtura , CNBC Business News said.

Gurus Trades with ZGEN: Click to exclude managers not in the List of Gurus. *The price and date might not be the actual time and price at which the transactions were made.

“I think what's most meaningful are what are our sales, what are their sales”

Last week, ZymoGenetics' announcement that a substantial number of hospitals were deciding to carry Recothrom, its first product, exclusively was quickly overshadowed by the release of a letter from the FDA ... via Seattle Post-Intelligencer

ZymoGenetics, Inc. today announced that results from Interleukin 21 studies will be presented or published at the American Society of Clinical Oncology 2008 annual meeting. via Earth Times

ZymoGenetics, Inc. announced today that Douglas E. Williams, Ph.D., President and Chief Scientific Officer, will provide an update on company - 05/14/2008 - 06:00 AM CHICAGO-- --Joelle K. Blomquist has joined ... via Business Wire